Devices Target the Gut to Maintain Weight Loss from GLP-1 Drugs (IEEE Spectrum)

As GLP-1 drugs transform weight loss, a quieter question is gaining urgency: how do patients hold on to those gains once the injections stop? This piece explores a new class of minimally invasive, gut-targeting devices designed to stabilize metabolism after drug-induced weight loss—without weekly shots or lifelong therapy. Early trial results are closely watched, skepticism remains, and multiple approaches are racing toward clinical validation. Whether these one-time procedures represent a durable next chapter in obesity care is becoming one of the most consequential debates heading into 2026, with Fractyl Health emerging as an early contender.